The SHL Perspective

Empowering Innovation

SHL's Molly® is an autoinjector designed to address various fill volumes of complex biologics. Built upon a preconfigured technology, Molly® aims to support shortened development timelines for pharmaceutical companies.

Feb 5-6 Paris, France Booth C64

Learn more at 2020 Pharmapack Europe

Molly® 2.25 is a large volume variation of the Molly® autoinjector, enabling it to accommodate the high volume requirement of complex biologics. With an upgrade in industrial design that is optimized for production, the new Molly® is designed to meet the evolving requirements of future autoinjectors such as scalable manufacturing.

The Molly® autoinjector supports fill volumes in the 1-2.25 mL range, enabling it to accommodate various volume requirements of complex biologics. Molly® is easy-to-use with its two-step operation, and is designed with a flange-shaped cap to prevent unwanted rolling.

Molly® 2.25

Molly® is an incredibly intuitive and easy-to-use autoinjector built with a preconfigured technology developed to minimize customer investments and speed up development timelines.

Bigger Volume

Close

Built for higher volume injections, Molly® 2.25 supports the trends for injection volumes in the 1-2.25mL range. This allows new drugs to be delivered in autoinjector and launched products to be dosed less frequently.

Better Grip

Close

Deepened ridges on Molly®’s cap enhances grip. Its flange-shaped top facilitates cap removal, and its rectangular contour prevents unwanted rolling to ance the device’s safety.

Easier Handling

Close

As a preconfigured offering, Molly® 2.25 is designed to be easily understood and accepted by a variety of patient groups. Having inherited the classic Molly®’s 2-step process, Molly® 2.25 is as compact, intuitive and easy to use.

Faster Timelines

Close

SHL’s final assembly, labeling and packaging services were established to create added value for our partners following the successful design and development of their device, resulting in a fully integrated service from device design to commercialization.

Preconfigured Technology

Close

A high-volume variation of SHL's classic Molly® autoinjector, Molly® 2.25 is a preconfigured device that can also support various levels of customization to meet client specifications. 

Preconfigured Technology

A high-volume variation of SHL's classic Molly® autoinjector, Molly® 2.25 is a preconfigured device that can also

support various levels of customization

to meet client specifications. 

Easier Handling

As a preconfigured offering, Molly® 2.25 is designed to be easily understood and accepted by a variety of patient groups. Having inherited the classic Molly®’s 2-step process, Molly® 2.25 is as compact, intuitive and easy to use.

Refined Design

Deepened ridges on Molly®’s cap enhances grip. Its flange-shaped top facilitates cap removal, and its rectangular contour prevents unwanted rolling to enhance the device’s safety.

Bigger Volume

Built for higher volume injections, Molly® 2.25 supports the trends for injection volumes in the 1-2.25mL range. This allows new drugs to be delivered in autoinjector and launched products to be dosed less frequently.

Faster Timelines

SHL’s final assembly, labeling and packaging services were established to create added value for our partners following the successful design and development of their device, resulting in a fully integrated service from device design to commercialization.

Molly® 2.25 is a large volume variation of the Molly® autoinjector, enabling it to accommodate the high volume requirement of complex biologics. With an upgrade in industrial design that is optimized for production, the new Molly® is designed to meet the evolving requirements of future autoinjectors such as scalable manufacturing.

The Molly® autoinjector supports fill volumes in the 1-2.25 mL range, enabling it to accommodate various volume requirements of complex biologics. Molly® is easy-to-use with its two-step operation, and is designed with a flange-shaped cap to prevent unwanted rolling.

Go to article: Home | US excess vs. global accessGo to article: EditorialGo to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: ContentsGo to article: ELPRO Monitoring SolutionsGo to article: NewsGo to article: BaxterGo to article: The pharma industry briefingGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: Turning pharma green: an eco-wish list for the industryGo to article: Scandinavian Health Company InsightGo to article: Scandinavian HealthGo to article: Q&A: disrupting DNA synthesis with Twist’s Emily LeproustGo to article: Phoenix Company InsightGo to article: PhoenixGo to article: Tips and tricks for regulating advanced therapiesGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Lyme disease: what's actually going on here?Go to article: Subcuject Company Insight Go to article: SubcujectGo to article: The US and the developing world: a tale of two opioid crises Go to article: KugelmeiersGo to article: Tracking priority medicines in transit: UPS launches tech-enabled serviceGo to article: Modality SolutionsGo to article: When deadlines turn deadly: examining the psychology of drug regulatorsGo to article: Zenatek Go to article: Proteus Digital Health: a sharp lesson for smart pills?Go to article: MimotopesGo to article: Deals in brief powered by GlobalDataGo to article: MicronovaGo to article: The key list powered by GlobalDataGo to article: EmisphereGo to article: Markets and Indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: Air FranceGo to article: EventsGo to article: ILC Dover Go to article: Next issue